Contineum Therapeutics Inc (CTNM)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$8.81-10.01%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · CTNM
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -53.4% |
| Our one-year growth estimate | diamond | -93.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 39.9 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 65 industry peers · Company calendar date is not available
CTNM — earnings miss
Dated 2026-11-03
Results of Operations and Financial Condition. On November 3, 2026, Contineum Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2026. A copy of the press release is furnished herewith as Exhibit 99.1. The information contained in this Current Report on Form 8-K under Item 2.02 (including Exhibit 99.1) hereto is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the…
Why it matters: The company has no approved drug sales and reported a $15.2 million quarterly loss. Cash trends matter as its trials continue.
Worry ifQuarterly reports show cash and marketable securities remain near the mid-2029 runway plan. No financing is needed.
Less concerning ifCash use rises enough that the company cuts the mid-2029 runway view or raises new capital to fund planned trials.
Why it matters: PIPE-791 is Contineum's lead clinical program. Timely enrollment keeps the 324-patient trial moving toward its week 26 lung test.
Supportive ifCompany updates show PROPEL-IPF enrollment continues. The trial is still on track to finish as planned.
Worry ifCompany reports slower enrollment or a delay to the planned trial finish.
Why it matters: The Phase 2 trial missed its main measure in depression. J&J's review of other planned measures may decide whether PIPE-307 moves forward.
Watch forJ&J names a next trial for PIPE-307 or says planned measures support further study.
Also watch forJ&J ends PIPE-307 work in depression or says the other trial data do not support more study.
Why it matters: The early pain trial found pain scores improved more than placebo, but it was exploratory. A larger trial would test that signal more firmly.
Supportive ifContineum starts a larger PIPE-791 pain trial and names its patient count and main pain measure.
Worry ifContineum says it will not advance PIPE-791 for pain, or reports safety concerns that stop further testing.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$214 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $706 loss on $10,000 · 7.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $5,970 loss on $10,000 · 59.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The trial's main test is the change in lung capacity. A clear benefit over placebo would support PIPE-791 in IPF.
Supportive ifAt the 26-week readout, PIPE-791 improves FVC more than placebo, with a clear difference between groups.
Worry ifAt the 26-week readout, PIPE-791 does not improve FVC more than placebo, or the trial misses its main test.